NASDAQ: CGTX - Cognition Therapeutics, Inc.

Yield per half year: -28.25%
Dividend yield: 0.00%
Sector: Healthcare

Share chart Cognition Therapeutics, Inc.

Extended chart Simple chart
Financial Markets by TradingView

About Cognition Therapeutics, Inc.

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex for the treatment of Alzheimer's disease.

more details
The company is also developing COG0201 SHINE, a randomized double-blind and placebo-controlled for mild-to-moderate AD and is in phase II clinical trial. Its product pipeline also includes CT2168 for Synucleinopathies; and CT2074 for dry age-related macular degeneration. The company was incorporated in 2007 and is headquartered in Purchase, New York.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 2021-10-08
ISIN US19243B1026
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.cogrx.com
Цена ао 0.495
Change price per day: -0.7419% (0.4583)
Change price per week: -22% (0.5832)
Change price per month: -40.21% (0.7608)
Change price per 3 month: +13.16% (0.402)
Change price per half year: -28.25% (0.634)
Change price per year: -77.26% (2)
Change price per 3 year: -84.47% (2.93)
Change price per 5 year: 0% (0.4549)
Change price per 10 year: 0% (0.4549)
Change price per year to date: -39.35% (0.75)
All parameters

Underestimation

Title Value Grade
P/S 0 0
P/BV 2.16 7
P/E 0 0
EV/EBITDA -0.4577 0
Total: 3.38

Efficiency

Title Value Grade
ROA, % -73.34 0
ROE, % -105.37 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -0.0034 10
Total: 9.8

Growth impulse

Title Value Grade
Yield Revenue, % 0 0
Yield Ebitda, % 628.83 10
Yield EPS, % 163.99 10
Total: 8
More

Institutions Volume Share, %
Pathstone Holdings, LLC 2205377 5.65
AIGH Capital Management LLC 2038853 5.23
Vanguard Group Inc 721554 1.85
Worth Venture Partners, LLC 508719 1.3
Carlson Capital. L.P. 238000 0.61
Kestra Advisory Services, LLC 219434 0.56
American Financial Group Inc. 205000 0.53
Geode Capital Management, LLC 174798 0.45
Mercer Global Advisors, Inc./ADV 130951 0.34
Commonwealth Equity Services, LLC 92730 0.24

ETF Share, % Profitability for 1 year, % Dividends, %
iShares Micro-Cap ETF 0.00461 17.09 1.54048



Head Job title Payment Year of birth
Ms. Lisa Ricciardi CEO, President & Director 854.15k 1960 (65 years)
Dr. Anthony O. Caggiano M.D., Ph.D. Chief Medical Officer and Head of R&D 616.27k 1970 (55 years)
Mr. John Brendan Doyle Chief Financial Officer 414.88k 1977 (48 years)
Dr. Steven A. Weissman Ph.D. VP & Head of CMC N/A
Ms. Anita Cornet Head of Quality
Mr. Bobby Horn Corporate Controller

Address: United States, Purchase. NY, 2500 Westchester Avenue - open in Google maps, open in Yandex maps
Website: https://www.cogrx.com